Lead Product(s) : Naproxen Sodium
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides receives USFDA approval for Naproxen Sodium OTC Softgel Capsules
Details : USFDA approved generic version of naproxen sodium, a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps.
Product Name : Naproxen Sodium-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 18, 2022
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dr. Reddy’s OTC Naproxen Sodium Tablets USP, 220 mg is an over-the-counter nonsteroidal antiinflammatory drug (NSAID) for use as a pain reliever and fever reducer. It temporarily relieves minor aches and pains.
Product Name : Naproxen Sodium-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2021
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naproxen Sodium,Diphenhydramine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules India Receives FDA Approval for Naproxen Sodium/Diphenhydramine Tablets
Details : Generic of Naproxen Sodium and Diphenhydramine HCl Tablets are approved for relief of occasional sleeplessness associated with minor aches and pains and to help you fall asleep and stay asleep.
Product Name : Aleve-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2020
Lead Product(s) : Naproxen Sodium,Diphenhydramine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | University of Chicago | University of Oklahoma
Deal Size : Inapplicable
Deal Type : Inapplicable
NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain
Details : Naproxen Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dysmenorrhea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | University of Chicago | University of Oklahoma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Orion Corporation
Deal Size : $0.6 million
Deal Type : Licensing Agreement
Searchlight Pharma Announces Suvexx® Launch in Europe, Along with Deal Expansion to all E.U. Markets
Details : The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U....
Product Name : Suvexx
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 15, 2023
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Orion Corporation
Deal Size : $0.6 million
Deal Type : Licensing Agreement
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : US Department of Defense | Endeavor Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sodium Naproxen is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dysmenorrhea.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : US Department of Defense | Endeavor Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naproxen Sodium,Pseudoephedrine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naproxen Sodium and Pseudoephedrine Hydrochloride Sustained Release Tablets (brand name, Pusen OK), in which the compound ingredient pseudoephedrine is in line with the cold symptom relief medicine recommended in the Catalog.
Product Name : Pusen OK
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : Naproxen Sodium,Pseudoephedrine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naproxen Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Postoperative Toothache.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estoni...
Product Name : Suvexx
Product Type : Miscellaneous
Upfront Cash : $2.0 million
December 21, 2020
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naproxen Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 13, 2020
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.
